Ultragenyx Pharmaceutical Inc. (RARE)
Market Cap | 2.74B |
Revenue (ttm) | 363.33M |
Net Income (ttm) | -707.42M |
Shares Out | 70.22M |
EPS (ttm) | -10.12 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 660,367 |
Open | 38.48 |
Previous Close | 38.53 |
Day's Range | 38.00 - 39.12 |
52-Week Range | 33.36 - 85.53 |
Beta | 0.94 |
Analysts | Buy |
Price Target | 93.67 (+140.18%) |
Earnings Date | May 4, 2023 |
About RARE
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysacc... [Read more]
Financial Performance
In 2022, RARE's revenue was $363.33 million, an increase of 3.39% compared to the previous year's $351.41 million. Losses were -$707.42 million, 55.8% more than in 2021.
Financial StatementsAnalyst Forecast
According to 25 analysts, the average rating for RARE stock is "Buy." The 12-month stock price forecast is $93.67, which is an increase of 140.18% from the latest price.
News

Ultragenyx Appoints Dr. Eric Crombez Chief Medical Officer and Executive Vice President
Dr. Camille Bedrosian to continue employment as strategic development advisor with the company Dr. Camille Bedrosian to continue employment as strategic development advisor with the company

Ultragenyx to Participate in Orphan Neuro Panel at Cowen Healthcare Conference
NOVATO, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for ser...

Ultragenyx (RARE) Q4 Earnings Miss, Revenues Increase Y/Y
Ultragenyx (RARE) reports a wider loss in the fourth quarter while revenues increase on growth in demand for its drugs.

Ultragenyx (RARE) Reports Q4 Loss, Tops Revenue Estimates
Ultragenyx (RARE) delivered earnings and revenue surprises of -6.40% and 0.27%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Ultragenyx Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Update
2022 Total Collaboration and Product Revenue of $355.6 million, Crysvita® revenue of $ 279.4 million and Dojolvi® revenue of $55.6 million

Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2022 Financial Results and Corporate Update
NOVATO, Calif., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for seri...

Ultragenyx (RARE) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
Ultragenyx (RARE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ultragenyx (RARE) Posts Preliminary '22 Results, Gives '23 View
Ultragenyx (RARE) reports preliminary product revenues for its marketed drugs, Crysvita, Mepsevii and Dojolvi for the full year 2022. The company issues product revenue guidance for 2023.

Ultragenyx Reports Preliminary 2022 Revenue; Guidance for 2023 Revenue and Cash Usage; Pipeline Updates and 2023 Milestones
Preliminary 2022 Total Product Revenue of $352 million to $356 million, Crysvita® Revenue in Ultragenyx Territories 1 of $257 million to $258 million and Dojolvi® revenue of $55 million to $56 million

Ultragenyx to Present at the 41st Annual J.P. Morgan Healthcare Conference
NOVATO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for ser...

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NOVATO, Calif., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rar...

Ultragenyx's (RARE) Portfolio of Marketed Drugs Aids Growth
Ultragenyx's (RARE) marketed drugs, which are approved for various indications, are driving the top line. The company also has a strong pipeline.

Ultragenyx to Present at Piper Sandler Healthcare Conference
NOVATO, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for ser...

Ultragenyx Announces Departure of Chief Financial Officer
NOVATO, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced that Mardi Dier, Chief Financial Officer (CFO) and Executive Vice President, is leaving the co...

Ultragenyx to Present at Upcoming Healthcare Conferences
NOVATO, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for ser...

Ultragenyx's (RARE) Q3 Earnings Miss Estimates, Revenues Up Y/Y
Ultragenyx (RARE) reports a wider-than-expected loss in the third quarter. Revenues, though up year over year, miss estimates.

Ultragenyx (RARE) Reports Q3 Loss, Misses Revenue Estimates
Ultragenyx (RARE) delivered earnings and revenue surprises of -6.11% and 8.16%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Ultragenyx to Host Conference Call for Third Quarter 2022 Financial Results and Corporate Update
NOVATO, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for seri...

Earnings Preview: Ultragenyx (RARE) Q3 Earnings Expected to Decline
Ultragenyx (RARE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ultragenyx and Mereo BioPharma to Present Setrusumab Data Update at ASBMR
NOVATO, Calif. and MOUNTAIN VIEW, Calif. and LONDON, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), (“Ultragenyx”), a biopharmaceutical company focused on the develo...

Ultragenyx to Participate at Citi BioPharma Conference
NOVATO, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for se...

Kyowa Kirin Receives European Commission Approval for Use of CRYSVITA®▼(burosumab) for the Treatment of Tumour-Induced Osteomalacia (TIO)
TOKYO, Japan--(BUSINESS WIRE)--Kyowa Kirin Co., Ltd. (TSE: 4151, Kyowa Kirin) today announced that the European Commission (EC) approved CRYSVITA® (burosumab) for the treatment of FGF23-related hypoph...

Ultragenyx's (RARE) Q2 Earnings Miss Estimates, Revenues Up
Ultragenyx (RARE) reports a wider-than-expected loss in the second quarter. Nevertheless, revenues marginally beat estimates.

Ultragenyx (RARE) Reports Q2 Loss, Tops Revenue Estimates
Ultragenyx (RARE) delivered earnings and revenue surprises of -31.40% and 0.84%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Ultragenyx Reports Second Quarter 2022 Financial Results and Corporate Update
Second quarter 2022 total revenue of $89.3 million and Crysvita® revenue in Ultragenyx territories 1 of $64.0 million